Albireo Pharma Inc. (NASDAQ:ALBO), whose market capitalization now stands at $158.02M, reported EPS of $-11.50 in the last financial year. That indicates the stock has price-to-earnings ratio of – at the prevailing stock price. This fiscal year’s EPS is projected to grow -104.60% over the preceding year.
For the forward P/E metric, market analysts have a 12-month target price of $40.00 on the stock of Albireo Pharma, Inc..
Over the preceding five years, Albireo Pharma, Inc. has recorded EPS improvement of 25.40%.
Let’s look into the charts of the stock
The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
Analysts are projecting the stock of Albireo Pharma, Inc. to be trading at $40.00 in the next 12-months, but what been its performance quality until now?
The stock jumped/declined 2.97% in the previous week, and for the preceding month it is up/down -14.49%. For the quarter and for the fiscal year so far, the shares have risen/decline -21.36% and 5.47%, respectively. From a year earlier, the stock has moved 97.88%.
What about the volatility of the equity? First, the stock’s beta is 1.42. Investors would do well to note that beta of less than 1 indicates that the underlying security is less volatile as against the market, but beta over one implies that a security is extremely volatile compared to market.
In terms of monthly or weekly volatility, Albireo Pharma, Inc. has a weekly volatility of 11.22% and monthly volatility of 7.73%.
Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 2,200,000 shares of its common stock at a price to the public of $20.50 per share. In addition, the underwriters have exercised an option to purchase an additional 330,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by Albireo, with gross proceeds to Albireo of approximately $51.9 million and net proceeds of approximately $48.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.